Study examines new treatment for recurrent urinary tract infections

Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women. A depletion of vaginal lactobacilli, a type of bacteria, is associated with urinary tract infection risk, which suggests that replenishing these bacteria may be beneficial. Researchers conducted a double-blind placebo-controlled trial to investigate this theory. Their results are published in Clinical Infectious Diseases.

In the study, young with a history of recurrent received for acute urinary tract infections. They were then randomized to receive either a Lactobacillus crispatus intravaginal suppository probiotic, called LACTIN-V, or a placebo for five days, then once a week for 10 weeks.

The results suggest that the probiotic may reduce the rate of recurrent urinary tract infections in women prone to these infections. Of the 100 women who participated in the study, 50 received LACTIN-V, and 50 received the placebo. Seven of the women who received LACTIN-V had at least one urinary tract infection, compared to 13 in the placebo group.

According to study author Ann Stapleton, MD, of the University of Washington in Seattle, "Larger efficacy trials of this novel preventive method for recurrent urinary tract infections are warranted to determine if use of vaginal could replace long-term antimicrobial preventive treatments."

More information: Randomized, Placebo-controlled Phase 2 Trial of a Lactobacillus crispatus Probiotic Given Intravaginally for Prevention of Recurrent Urinary Tract Infection www.oxfordjournals.org/our_journals/cid/cir183.pdf

add to favorites email to friend print save as pdf

Related Stories

FDA OKs urinary infection injectable drug

Oct 18, 2007

The U.S. Food and Drug Administration announced approval Thursday of doripenem (Doribax) injections for the treatment of complex urinary tract infections.

Recommended for you

Noninvasive devices may help migraines, FDA says

19 minutes ago

(HealthDay)—Two new prescription devices approved by the U.S. Food and Drug Administration (FDA) may provide some relief for people with migraine headaches who don't tolerate migraine medications well, ...

Lessons learned six months into worst Ebola outbreak

5 hours ago

Six months into the biggest-ever Ebola outbreak, scientists say they know more about how the deadly virus behaves. The first cases were reported in Guinea by the World Health Organization on March 23—before ...

User comments